On 3 December 2018, GlaxoSmithKline (GSK) announced that it will be acquiring Tesaro...
The clinical trial landscape for GSK’s latest acquisition Tesaro
On 3 December 2018, GlaxoSmithKline (GSK) announced that it will be acquiring Tesaro to bolster its drug development portfolio, especially in oncology. With the help of GlobalData’s Pharma Intelligence Center database, a look at Tesaro’s clinical trial landscape can provide an analysis of potential R&D plans.
Bristol-Myers and Vedanta to study combination therapy for cancer
Bristol-Myers Squibb has partnered with PureTech Health subsidiary Vedanta Biosciences to study its Opdivo in combination with VE800 drug candidate for the treatment of advanced or metastatic cancers.
Allergan’s Phase III Botox trial for depression pushed to H2 2019
Allergan’s Botox (onabotulinumtoxin A) Phase III trial in major depressive disorder (MDD) is slated to initiate in the second half of 2019 (2H19), said a company spokesperson.
Foamix’s rosacea drug FMX103 splits views on sunburn risk
Foamix Pharmaceuticals’ FMX103 (1.5% topical minocycline foam) has experts split over the drug’s real-world ability to protect against sunburn, despite expected FDA approval for moderate-to-severe facial papulopustular rosacea.
ASH 2018: Celgene’s Revlimid looks set for new approvals in NHL
Data from the Phase III AUGMENT trial assessing Revlimid plus rituximab in relapsed/refractory (R/R) indolent lymphoma was presented during the second day of the 2018 American Society of Hematology (ASH) conference.
AbbVie halts phase III TAHOE trial of Rova-T for SCLC
Following advice from an independent data monitoring committee, biopharma company AbbVie has ceased enrolment in its TAHOE trial evaluating Rovalpituzumab Tesirine (Rova-T) as a second line therapy for patients with advanced or metastatic small-cell lung cancer (SCLC).
Breast cancer clinical trials: top drugs under investigation
Breast cancer is the most commonly diagnosed cancer in women and the second most commonly diagnosed cancer overall.
Enrollment issues are the top factor in clinical trial terminations
GlobalData analysed all terminated trials within the Clinical Trials Database to determine the major reasons for terminations.
Are you a manufacturer, importer, distributor or wholesaler of healthcare products? RAQAC has the specialised knowledge to help you navigate the Canadian regulatory requirements for registering and marketing products.
Distek Model 2500 Dissolution System
The Distek Model 2500 dissolution system offers great flexibility and configurability. It
can be configured as US Pharmacopoeia (USP) Apparatus 1, 2, 5 and 6 plus intrinsic dissolution.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.